Chemotherapy induced thrombocytopenia in pediatric oncology

Tamamyan, Gevorg; Danielyan, Samvel; Lambert, Michele P.

doi:10.1016/j.critrevonc.2016.01.005

Cited by 25 publications

(44 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No patients experienced adverse events related to romiplostim or venous thrombosis during or after the timeframe of this series. Romiplostim has a risk of leukemic clone proliferation that may limit its use in children with hematologic malignancies . None of our patients showed evidence of myelodysplastic syndrome or hematologic malignancy prior to, during, or after romiplostim therapy.…”

Section: Discussionmentioning

confidence: 76%

“…Thrombocytopenia is a common complication of cancer therapy in children, and prolonged thrombocytopenia causes significant therapy delays and dose reductions. Currently, platelet transfusion is the only widely accepted intervention for TRT in pediatrics . Platelet transfusions can result in adverse reactions in up to 30% of patients .…”

Section: Discussionmentioning

confidence: 99%

“…Currently, platelet transfusion is the only widely accepted intervention for TRT in pediatrics. 1 Platelet transfusions can result in adverse reactions in up to 30% of patients. 8 Serial transfusions can cause alloimmunization and loss of efficacy, 9 and transfused platelets decrease circulating thrombopoietin leading to decreased platelet production in the bone marrow.…”

Section: Discussionmentioning

confidence: 99%

“…In pediatric oncology, platelet transfusion is the standard treatment for TRT. 1,2 Romiplostim, an injectable thrombopoietin (TPO) mimetic, is FDA approved for chronic immune thrombocytopenia (cITP) in adults and was efficacious and well-tolerated in two Phase 3 studies in children with cITP. [3][4][5] Efficacy of romiplostim for TRT in adults with cancer has been demonstrated, 6,7 but there are no published reports in children.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Romiplostim for therapy‐related thrombocytopenia in pediatric malignancies

Jacobson

Shah

Setty

2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Therapy-related thrombocytopenia (TRT), due to chemotherapy and/or radiation therapy, is common with pediatric cancer treatments, and it can result in dose reductions and therapy delays. Romiplostim, a thrombopoietin mimetic, is efficacious as a second-line treatment for immune thrombocytopenia in children and for TRT in adult cancer patients. However, there are no data for its use for TRT in children. We report a case series of five children treated for solid tumors where romiplostim was used without adverse effects to successfully resolve and prevent therapy-limiting refractory TRT. Prospective studies on this use of romiplostim are warranted.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Romiplostim for therapy‐related thrombocytopenia in pediatric malignancies

Jacobson

Shah

Setty

2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…2,3 In addition to the morbidity related to bleeding, treatmentrelated thrombocytopenia can lead to delay or dose reduction in treatment and decreased treatment efficacy. 4 For children with cancer, transfusions are typically administered prophylactically to prevent bleeding. 5 Pediatric oncology-specific trials regarding the optimal pretransfusion platelet threshold have not been performed and ordering practice is not standardized.…”

mentioning

confidence: 99%

Platelet transfusion practice and platelet refractoriness for a cohort of pediatric oncology patients: A single‐center study

Lieberman

Liu

Barty

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Platelet transfusions are an essential aspect of supportive care for pediatric oncology patients. Data regarding the frequency of transfusions, pretransfusion thresholds, posttransfusion increments, and rate of platelet transfusion refractoriness (PTR) are lacking. Study objectives: (a) describe platelet transfusion practice for children with malignancy; (b) determine the normal platelet increment following platelet transfusion; and (c) assess rate of PTR. Methods: Inpatient pediatric oncology patients <18 years old and treated between 2009 and 2013 were identified. Data collected retrospectively included patient demographics, clinical information, laboratory values, and transfusion details. Results: Three hundred sixty-seven children were included and 144 (39%) received at least one platelet transfusion. Platelets were transfused during 25% of all inpatient admissions. The median number of platelet transfusion for any given inpatient admission was two (interquartile range [IQR]: 1-3). The median pretransfusion platelet count was 16 × 10 9 /L and posttransfusion increment was 25 × 10 9 /L. Most (79%) of the time, the pretransfusion platelet count was >10 × 10 9 /L. Older children who received ABO incompatible platelet transfusions with a longer storage duration were more likely to have a poor platelet response (increment ≤ 10 × 10 9 /L). The rate of PTR (immune and/or nonimmune) was low (8%; 11/144). Conclusions: Practical information to parents and clinicians of newly diagnosed children regarding the likelihood and frequency of platelet transfusions was determined. The rate of PTR was low, supporting the hypothesis that children receiving leukoreduced products are at a low risk of PTR.

show abstract

Novel approach to decrease platelet exposure in a pediatric Jehovah Witness patient

Cruickshank

Koury

2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Chemotherapy induced thrombocytopenia in pediatric oncology

Cited by 25 publications

References 92 publications

Romiplostim for therapy‐related thrombocytopenia in pediatric malignancies

Romiplostim for therapy‐related thrombocytopenia in pediatric malignancies

Platelet transfusion practice and platelet refractoriness for a cohort of pediatric oncology patients: A single‐center study

Novel approach to decrease platelet exposure in a pediatric Jehovah Witness patient

Contact Info

Product

Resources

About